Artelo Biosciences Inc (NAS:ARTL)

$ 1.06 0.01 (0.95%) Market Cap: 3.42 Mil Enterprise Value: -1.36 Mil PE Ratio: 0 PB Ratio: 0.54 GF Score: 32/100

Artelo Biosciences Inc at Benzinga All Access Event (Virtual) Transcript
Jul 11, 2023
Artelo Biosciences Inc Annual Shareholders Meeting Transcript
Jun 30, 2023
Artelo Biosciences Inc at Issuer Direct Winter Wonderland Best Ideas Investor Conference (Virtual) Transcript
Feb 22, 2023
Artelo Biosciences Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Feb 02, 2023
Artelo Biosciences Inc at LD Micro Main Event Transcript
Oct 25, 2022
Artelo Biosciences Inc at Ladenburg Thalmann Healthcare Conference Transcript
Sep 29, 2022
Artelo Biosciences Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Artelo Biosciences Inc at LD Micro Invitational Conference (Virtual) Transcript
Jun 07, 2022
Artelo Biosciences Inc at MicroCap Rodeo: Spring Into Action -- Best Ideas Virtual Investor Conference (Virtual) Transcript
May 16, 2022
Artelo Biosciences Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021

Artelo Biosciences Inc at LD Micro Main Event Transcript

Oct 25, 2022 / 08:30PM GMT

Release Date Price: $2.78 (+0.36%)

Transcript 10-Q

Unidentified Participant

Our next presenter is Greg Gorgas with our Artelo Biosciences. Take it away.

Greg Gorgas

Artelo Biosciences, Inc. - President & CEO

Thank you very much, and thank you to everybody in attendance. It's great to be with you here at the LD Micro Main Event. I will be making some forward-looking statements today. We would ask everybody to please go to our artelobio.com, where all of our SEC filings can be found in links on the website.

Artelo Biosciences is a clinical-stage company. We're focused in on lipid-signaling modification. And aim to treat cancer, cancer supportive care, and other related serious diseases.

Five things I'd like to communicate with you today about. One, is that we have a novel drug pipeline, multiple assets in the clinic and pre-clinical stage; near-term milestones over the next 3, 6, and 12 months; billion-dollar market opportunities across our entire portfolio of assets. This is underpinned by a very robust patent estate, and it's led by a proven leadership team that knows what finished and good looks

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.